TaylorAJ, VillinesTC, StanekEJ, DevinePJ, GriffenL, MillerM, WeissmanNJ, TurcoM. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med, 2009; 361:2113–2122.
6.
WeberO, BischoffH, SchmeckC, BöttcherMF. Cholesteryl ester transfer protein and its inhibition. Cell Mol Life Sci, 2010; 67:3139–3149.
7.
SchaeferEJ, AsztalosBF. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Am J Cardiol, 2007; 100:n25–n31.
8.
BarterPJ, CaulfieldM, ErikssonM, GrundySM, KasteleinJJ, KomajdaM, Lopez-SendonJ, MoscaL, TardifJC, WatersDD, ShearCL, RevkinJH, BuhrKA, FisherMR, TallAR, BrewerB. ILLUMINAATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007; 357:2109–2122.
9.
JialalI, KaurJ. The cholesterol ester transfer protein inhibitor, anacetrapib. Curr Opin Lipidol, 2011; 22(In press).
10.
KrishnaR, AndersonMS, BergmanAJ. Et al. Effect of the cholesterol ester transfer protein inhibitor, anacetrapib, on lipid proteins in patients with dyslipidemia and on 24-h ambulatory blood pressure in healthy invdividuals: Two double-blind, randomised placebo-controlled phase I studies. Lancet, 2007; 370:1907–1914.
11.
BloomfieldD, CarlsonGL, SapreA, TribbleD, McKenneyJM, LittlejohnTW, McCrary SiskC, MitchelY, PasternakRC. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and co administered with atorvastatin in dyslipidemic patients. Am Heart J, 2009; 157,2:352e2–360e2.
12.
CannonCP, ShahS, DanskyHM, DavidsonM, BrintonEA, GottoAM, StepanavageM, LiuSX, GibbonsP, AshrafTB, ZafarinoJ, MitchelY, BarterP. Determining the efficacy and tolerability investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med, 2010; 363:2406–2415.
13.
Yvan-CharvetL, KlingJ, PaglerT, LiHongna, HubbardB, FisherT, SparrowC, TaggartA, TallA. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol, 2010; 30:1430–1438.
14.
SteinEA, RothEM, RhyneJM, BurgessT, KallendD, RobinsonJG. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): Results from a 48-week trial. Eur Heart J, 2010; 31:480–488.
15.
RobinsonJG. Dalcetrapib: A review of Phase II data. Expert Opin Investig Drugs, 2010; 19:795–805.
